Immunovaccine hires John Trizzino as ceo

Vaccine specialist brings 25 years of experience to the role

Immunovaccine, a Canadian developer of vaccines, has appointed John Trizzino as chief executive. He will also join the board of directors of the firm upon joining on 1 October.

Trizzino has focused his career on vaccine development, manufacturing and distribution in the US and worldwide.

He joins Immunovaccine from Novavax, a clinical-stage vaccine company in Rockville, Maryland, where he was senior vice president.

Prior to this, he held senior executive positions at MedImmune, acquired by AstraZeneca, and ID BioMedical, now part of GlaxoSmithKline.

He began his broad-based career in vaccines at Henry Schein.

‘As our development programme accelerates with a second cancer vaccine in the clinic, we are pleased to be joined by someone with John's experience in partnering, licensing and distribution,’ said Albert Scardino, chairman of Immunovaccine.

‘The next phase of our development includes expanding the commercial potential of our early stage research partnerships. That is John's specialism. He knows the public markets, private financing and government contracting, and with his broad experience in the biotechnology industry, we anticipate a high level of visibility for our pioneering delivery platform and our vaccines.’

Immunovaccine develops vaccines for treating cancer and for the prevention of infectious disease.

The firm's DepoVax platform is a patented lipid delivery system that presents antigens plus adjuvant to the immune system for a prolonged period and has the potential to enhance immune responses.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

Zika outbreak gives rise to global fears

Zika may not be a new virus but its newly confirmed ability to cause foetal brain abnormalities makes the search for a treatment or a vaccine a high priority. Dr Sarah Houlton looks at the latest initiatives
Research & Development

Immunovaccine licenses cancer vaccine from Merck KGaA

Builds on clinical studies by formulating vaccine in DepoVax system
Distribution

Tower Cold Chain’ industry-first shipping container design

The pyramidal solution allows pharmaceuticals to be shipped at a consistent temperature between -60°C to above +20°C for up to 96 hours
Pharmaceutical

High-precision temperature control solutions for the pharmaceutical industry and biotechnology, available in the UK from Labtex

Huber offers a world-renowned range of temperature control systems and associated accessories for the Pharmaceutical Industry and Biotechnology
Sustainability

Building strong foundations for a resilient and planet-friendly future

Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Sustainability

Dickson achieves ISO 14001 certification

ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
Regulatory

The key role of IVDs in healthcare: challenges to commercialisation and access

In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
Subscribe now